Tien Dam

1.4k total citations
14 papers, 231 citations indexed

About

Tien Dam is a scholar working on Neurology, Physiology and Cognitive Neuroscience. According to data from OpenAlex, Tien Dam has authored 14 papers receiving a total of 231 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Neurology, 4 papers in Physiology and 3 papers in Cognitive Neuroscience. Recurrent topics in Tien Dam's work include Parkinson's Disease Mechanisms and Treatments (11 papers), Neurological disorders and treatments (7 papers) and Botulinum Toxin and Related Neurological Disorders (4 papers). Tien Dam is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (11 papers), Neurological disorders and treatments (7 papers) and Botulinum Toxin and Related Neurological Disorders (4 papers). Tien Dam collaborates with scholars based in United States, Canada and United Kingdom. Tien Dam's co-authors include Irene Litvan, Günter U. Höglinger, Feiby L. Nassan, Cathy Lally, Danielle Graham, Joseph Kupferman, Anthony E. Lang, Christopher S. Simpson, Nancy N. Maserejian and Lisa Vinikoor-Imler and has published in prestigious journals such as Nature Medicine, Neurology and Movement Disorders.

In The Last Decade

Tien Dam

13 papers receiving 230 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tien Dam United States	6	133	98	50	44	32	14	231
Peter A. Ljubenkov United States	8	91 0.7×	135 1.4×	33 0.7×	45 1.0×	45 1.4×	19	222
Nahome Fisseha United States	3	89 0.7×	58 0.6×	31 0.6×	19 0.4×	19 0.6×	6	176
Emily J. Hill United States	7	61 0.5×	128 1.3×	32 0.6×	42 1.0×	67 2.1×	19	243
Balvindar Singh United States	5	93 0.7×	82 0.8×	68 1.4×	48 1.1×	36 1.1×	5	197
Alfredo Megaro Italy	8	80 0.6×	78 0.8×	110 2.2×	34 0.8×	86 2.7×	12	258
Francesca Frangipane Italy	11	62 0.5×	134 1.4×	30 0.6×	55 1.3×	92 2.9×	17	253
Deborah Masliah United States	4	86 0.6×	113 1.2×	57 1.1×	88 2.0×	71 2.2×	4	221
R. Matthew Hutchison United States	9	95 0.7×	51 0.5×	48 1.0×	42 1.0×	29 0.9×	14	278
Pernille Louise Kjeldsen Denmark	6	54 0.4×	146 1.5×	30 0.6×	88 2.0×	47 1.5×	8	249
Xavier Taylor United States	10	66 0.5×	150 1.5×	33 0.7×	132 3.0×	61 1.9×	11	280

Countries citing papers authored by Tien Dam

Since Specialization

Citations

This map shows the geographic impact of Tien Dam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tien Dam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tien Dam more than expected).

Fields of papers citing papers by Tien Dam

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tien Dam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tien Dam. The network helps show where Tien Dam may publish in the future.

Co-authorship network of co-authors of Tien Dam

This figure shows the co-authorship network connecting the top 25 collaborators of Tien Dam. A scholar is included among the top collaborators of Tien Dam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tien Dam. Tien Dam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Simuni, Tanya, Caroline Gochanour, Michael C. Brumm, et al.. (2025). Neuronal α‐Synuclein Disease Stage Progression over 5 Years. Movement Disorders. 40(7). 1318–1330.

Mestre, Tiago, Glenn T. Stebbins, Diane Stephenson, et al.. (2024). Patient-centered development of clinical outcome assessments in early Parkinson disease: key priorities and advances. npj Parkinson s Disease. 10(1). 101–101. 4 indexed citations

Hutchison, R. Matthew, Kyle Fraser, Minhua Yang, et al.. (2024). Cinpanemab in Early Parkinson Disease. Neurology. 102(5). e209137–e209137. 18 indexed citations

Mammen, Jennifer R., Rebecca M. Speck, Glenn T. Stebbins, et al.. (2023). Relative Meaningfulness and Impacts of Symptoms in People with Early-Stage Parkinson’s Disease. Journal of Parkinson s Disease. 13(4). 619–632. 22 indexed citations

Mammen, Jennifer R., Rebecca M. Speck, Martijn L.T.M. Müller, et al.. (2023). Mapping Relevance of Digital Measures to Meaningful Symptoms and Impacts in Early Parkinson’s Disease. Journal of Parkinson s Disease. 13(4). 589–607. 19 indexed citations

Simpson, Christopher S., Lisa Vinikoor-Imler, Feiby L. Nassan, et al.. (2022). Prevalence of ten LRRK2 variants in Parkinson's disease: A comprehensive review. Parkinsonism & Related Disorders. 98. 103–113. 40 indexed citations

Viscidi, Emma, Irene Litvan, Tien Dam, et al.. (2021). Clinical Features of Patients With Progressive Supranuclear Palsy in an US Insurance Claims Database. Frontiers in Neurology. 12. 571800–571800. 19 indexed citations

Jaeger, Judith, Yumeng Li, Carmen Castrillo‐Viguera, et al.. (2021). Development of a cognitive composite for measuring change in progressive supranuclear palsy. Parkinsonism & Related Disorders. 92. 94–100. 3 indexed citations

Dam, Tien, Adam L. Boxer, Lawrence I. Golbe, et al.. (2021). Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. Nature Medicine. 27(8). 1451–1457. 93 indexed citations

10.

Ljubenkov, Peter A., Lawren VandeVrede, Julio C. Rojas, et al.. (2021). A phase 1b, randomized, double‐blind, placebo‐controlled, parallel cohort safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy study of intravenously infused BIIB092 in patients with four different primary tauopathy syndromes. Alzheimer s & Dementia. 17(S9). 1 indexed citations

11.

Dam, Tien, Adam L. Boxer, Lawrence I. Golbe, et al.. (2019). P1‐051: PARTICIPANT BASELINE CHARACTERISTICS IN PASSPORT, A PHASE 2 STUDY OF THE EFFICACY AND SAFETY OF BIIB092 FOR PROGRESSIVE SUPRANUCLEAR PALSY. Alzheimer s & Dementia. 15(7S_Part_4). 3 indexed citations

12.

Dam, Tien, Adam L. Boxer, Lawrence I. Golbe, et al.. (2018). Efficacy and Safety of BIIB092 in Patients with Progressive Supranuclear Palsy: PASSPORT Phase 2 Study Design (P6.073). Neurology. 90(15_supplement). 5 indexed citations

13.

Herring, W. Joseph, Ellen Snyder, Donald L. Bliwise, et al.. (2017). Clinical Trial Design for Assessment of the Orexin Receptor Antagonist Suvorexant in the Treatment of Insomnia in Patients with Alzheimer’s Disease (P3.066). Neurology. 88(16_supplement). 1 indexed citations

14.

Dam, Tien, et al.. (2006). IERS Working Group on Prediction Plans and Activities. AGUFM. 2006. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact